In our study, a heatmap was established to clearly observe the expression levels of integrin αvβ3/α6β1 and clinical characteristics, including PSA value, primary therapy outcome success, pathological T and N stages, Gleason score, treatment success and clinical T and N stages, of 496 PCa patients in the TCGA cohort, and the results implied that integrins ITGAV, ITGA6, ITGB1 and ITGB3 were closely associated with these clinical features (Figure 2A). Here, ITGB3 is linked to posterior cortical atrophy.